Related Experiment Video
Updated: Jun 13, 2026

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray
Published on: January 6, 2016
Antibody Engineering & Design 2010. 24-25 February 2010, Frankfurt, Germany
1Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
Abstract:
The Antibody Engineering & Design 2010 conference, held in Frankfurt, included topics covering new developments in the field of therapeutic antibodies. This conference report highlights selected presentations on 'fit for purpose' biologics, improving the pharmaceutical properties of antibodies, the selection of antibody fragments for therapeutic use, challenges in biopharmaceutical manufacturing, developing dual-targeting antibodies, epitope mapping, and the development of two novel mAbs. Investigational drugs discussed include 1D4.1-ABT325 (Abbott Laboratories), Sym-004 (Symphogen A/S) and CNTO-607 (Johnson & Johnson).
More Related Videos
Related Concept Videos
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity

